# CRISPR * **Definition:** A revolutionary gene-editing technology that allows for precise modifications to DNA, based on a bacterial antiviral defense system, enabling the modification of the genomes of living organisms. * **Taxonomy:** Healthcare Topics / CRISPR ## News * Selected news on the topic of **CRISPR**, for healthcare technology leaders * 6.5K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/14/2025 | [**CRISPR Market worth US$5.47 billion by 2030 with 11.2AGR - MarketsandMarkets™**](https://www.prnewswire.com/news-releases/crispr-market-worth-us5-47-billion-by-2030-with-11-2-cagr--marketsandmarkets-302454978.html) | [[PR Newswire]] | | 5/14/2025 | [**CRISPR Market worth US$5.47 billion by 2030 with 11.2AGR - MarketsandMarkets™**](https://finance.yahoo.com/news/crispr-market-worth-us-5-140100409.html) | [[Yahoo Finance]] | | 3/27/2025 | [**ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement**](https://www.prnewswire.com/news-releases/ers-genomics-and-jumpcode-genomics-sign-crisprcas9-license-agreement-302413371.html) | [[PR Newswire]] | | 3/27/2025 | [**ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement**](https://finance.yahoo.com/news/ers-genomics-jumpcode-genomics-sign-154900264.html) | [[Yahoo Finance]] | | 3/13/2025 | [**New CRISPRs expand research and biomedical applications upon original's abilities**](https://phys.org/news/2025-03-crisprs-biomedical-applications-abilities.html) | [[Phys Org]] | | 3/5/2025 | [**Could CRISPR Help Prevent the Next Global Pandemic?**](https://www.news-medical.net/health/Could-CRISPR-Help-Prevent-the-Next-Global-Pandemic.aspx) | [[News Medical Net]] | | 2/26/2025 | [**CRISPR Market is expected to generate a revenue of USD 12.78 Billion by 2032, Globally ...**](https://www.prnewswire.com/news-releases/crispr-market-is-expected-to-generate-a-revenue-of-usd-12-78-billion-by-2032--globally-at-15-85-cagr-verified-market-research-302386211.html) | [[PR Newswire]] | | 2/26/2025 | [**CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference**](https://finance.yahoo.com/news/crispr-therapeutics-present-td-cowen-130000248.html) | [[Yahoo Finance]] | | 1/7/2025 | [**CRISPR Therapeutics Proposes New Appointment to the Board of Directors**](https://www.globenewswire.com/news-release/2025/01/07/3005342/0/en/CRISPR-Therapeutics-Proposes-New-Appointment-to-the-Board-of-Directors.html) | [[Globe Newswire]] | | 1/7/2025 | [**CRISPR Technology Market: A Revolution in Genetic Engineering - by Nick Fury - Medium**](https://medium.com/@nf983118/crispr-technology-market-a-revolution-in-genetic-engineering-10c1dd43968d) | [[Medium]] | | 1/7/2025 | [**CRISPR Therapeutics Proposes New Appointment to the Board of Directors**](https://finance.yahoo.com/news/crispr-therapeutics-proposes-appointment-board-130000255.html) | [[Yahoo Finance]] | | 1/6/2025 | [**CRISPR Therapeutics Proposes New Appointment to the Board of Directors**](https://markets.businessinsider.com/news/stocks/crispr-therapeutics-proposes-new-appointment-to-the-board-of-directors-1034199362) | [[Business Insider Markets]] | | 12/14/2024 | [**3 Things You Need to Know if You Buy CRISPR Therapeutics Today - Yahoo Finance**](https://finance.yahoo.com/news/3-things-know-buy-crispr-144500777.html) | [[Yahoo Finance]] | | 12/13/2024 | [**Growth Trends in the CRISPR and Cas Gene Market - Yahoo Finance**](https://finance.yahoo.com/news/growth-trends-crispr-cas-gene-142700184.html) | [[Yahoo Finance]] | | 11/26/2024 | [**CRISPR Technology Market: A Revolution in Genetic Engineering - by Nick Fury - Medium**](https://medium.com/@nf983118/crispr-technology-market-a-revolution-in-genetic-engineering-db8c4bace0b0) | [[Medium]] | | 9/30/2024 | [**What is CRISPR? Unraveling the Secrets of Gene Editing Technology - by Gary A. Fowler**](https://medium.com/@gafowler/what-is-crispr-unraveling-the-secrets-of-gene-editing-technology-0f257150f956) | [[Medium]] | | 9/5/2024 | [**ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement**](https://www.news-medical.net/news/20240905/ERS-Genomics-and-medicines-discovery-catapult-sign-CRISPRCas9-license-agreement.aspx) | [[News Medical Net]] | | 9/4/2024 | [**VedaBio Appoints Dr. G. Brett Robb as Senior Scientific Director and Head of CRISPR Science**](https://finance.yahoo.com/news/vedabio-appoints-dr-g-brett-110000510.html) | [[Yahoo Finance]] | | 8/13/2024 | [**CRISPR QC Launches Three Innovative Products and Unveils Revamped Website**](http://www.businesswire.com/news/home/20240813130977/en/CRISPR-QC-Launches-Three-Innovative-Products-and-Unveils-Revamped-Website/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 8/13/2024 | [**CRISPR QC Launches Three Innovative Products and Unveils Revamped Website**](http://www.businesswire.com/news/home/20240813130977/en/CRISPR-QC-Launches-Three-Innovative-Products-and-Unveils-Revamped-Website/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 8/13/2024 | [**Harnessing compact RNA-guided endonucleases for enhanced genome editing**](https://phys.org/news/2024-08-harnessing-compact-rna-endonucleases-genome.html) | [[Phys Org]] | | 8/12/2024 | [**CRISPR Cas9 Market and Clinical Trials Report to 2029 - Yahoo Finance**](https://finance.yahoo.com/news/crispr-cas9-market-clinical-trials-085200472.html) | [[Yahoo Finance]] | | 8/8/2024 | [**CRISPR Gene Editing Market Forecasted to Reach New Heights by 2033 and In-Depth ...**](https://www.whatech.com/og/markets-research/medical/864648-crispr-gene-editing-market-forecasted-to-reach-new-heights-by-2033-and-in-depth-market-analysis.html) | whatech.com | | 8/6/2024 | [**CRISPR Technology Research Report 2024 - Now Available**](https://finance.yahoo.com/news/crispr-technology-research-report-2024-130800305.html) | [[Yahoo Finance]] | | 7/2/2024 | [**Top 10 CRISPR Companies - Best DNA Editors**](https://media.market.us/top-10-crispr-companies/) | media.market.us | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **CRISPR Therapeutics**: A gene-editing company known for its Casgevy® drug, approved for treating sickle cell disease and beta thalassemia. - **Innovative Genomics Institute**: A research institute focused on advancing CRISPR technology for therapeutic applications. - **ERS Genomics**: Holds a global portfolio of over 100 CRISPR/Cas9 patents and aims to broaden access to CRISPR technology through partnerships. - **Synthego**: Offers CRISPR solutions, including GMP-grade SpCas9, to facilitate therapeutic development. - **ERS Genomics Limited**: Holds a comprehensive portfolio of CRISPR/Cas9 patents and collaborates with Medicines Discovery Catapult. - **Caribou Biosciences**: Focused on developing CRISPR genome-edited therapies using advanced Cas12a technology. - **Integrated DNA Technologies**: Collaborated with the Innovative Genomics Institute to create CRISPR treatments for genetic disorders. - **Integrated DNA Technologies (IDT)**: A company enhancing CRISPR genome editing solutions through partnerships and advanced off-target analysis. - **SNIPR Biome**: A clinical-stage biotech company pioneering precision medicines using CRISPR technology for microbial gene therapy. ### Partnerships and Collaborations - **CRISPR Therapeutics and Bayer**: Strategic partnership aimed at enhancing research and development efforts in gene-based medicines. - **SNIPR Biome**: Received funding from the Bill & Melinda Gates Foundation for developing CRISPR-armed phages. - **Integrated DNA Technologies and Innovative Genomics Institute**: Collaborating to develop CRISPR treatments for genetic disorders. - **ERS Genomics and Jumpcode Genomics**: A non-exclusive license agreement to utilize CRISPR technology for next-generation sequencing. - **ERS Genomics and Medicines Discovery Catapult**: A non-exclusive commercial-use CRISPR license agreement to enhance drug discovery processes. - **SNIPR Biome and Novo Nordisk**: Collaboration to advance CRISPR technology for treating and preventing human diseases. - **Scribe Therapeutics and various organizations**: Announced advancements in CRISPR technologies for clinical trials. - **Vertex Pharmaceuticals and CRISPR Therapeutics**: Collaborate on the development of Casgevy, the first approved CRISPR therapy. - **CRISPR Therapeutics and Vertex Pharmaceuticals**: Strategic partnership to enhance research and development efforts in gene-based therapies. - **HuidaGene Therapeutics and Dr. TJ Cradick**: Focus on developing gene editing tools and delivery vectors. - **IDT and SeQure Dx**: Entered a licensing agreement to enhance CRISPR genome editing solutions with advanced off-target analysis capabilities. - **ERS Genomics and MDC**: Entered a non-exclusive commercial-use CRISPR license agreement to enhance drug discovery. - **Scribe Therapeutics and various partners**: Engaged in collaborations to enhance its CRISPR-based technologies for treating prevalent diseases. - **ERS Genomics and Université de Montréal**: A non-exclusive license agreement allowing the university to access CRISPR technology for research. - **ElevateBio and AWS**: A multi-year collaboration to enhance CRISPR gene editing for a broader range of genetic diseases using AI. ### Innovations, Trends, and Initiatives - **CRISPR-Cas9 Technology**: Revolutionizes gene editing by allowing precise modifications of DNA sequences, with applications in medicine, agriculture, and biotechnology. - **CRISPR√**: A new gene-silencing method developed by RIKEN that allows for highly accurate and reversible silencing of specific genes. - **CRISPR-Cas13 Development**: Emerging as a promising tool for RNA editing, allowing for temporary manipulation of gene expression. - **CRISPRkit**: A DIY gene-editing kit developed to democratize access to CRISPR technology for educational purposes. - **CRISPRi and CRISPRa Systems**: Provide precise gene regulation capabilities, allowing for both down-regulation and activation of gene expression. - **New CRISPR Systems**: Discovery of new CRISPR-Cas systems that enhance gene editing capabilities for human health applications. - **Next-generation CRISPR technologies**: Exploration of base editing and prime editing to minimize off-target effects and enhance therapeutic applications. - **CRISPR Analytics Platform by CRISPR QC**: A platform providing real-time insights into gRNA design efficiency and RNP stability to enhance gene editing. - **NanoCas™**: An ultracompact CRISPR system developed by Mammoth Biosciences, allowing for efficient gene editing in extrahepatic tissues. - **Bridge RNA Technology**: A new gene editing technique allowing for the addition, removal, and recombination of DNA sequences, addressing CRISPR limitations. - **CRISPR Applications**: Significant applications in genome engineering, with the epigenetics segment expected to grow rapidly. - **Focused Ultrasound-CRISPR**: A novel approach integrating focused ultrasound with CRISPR to enable targeted gene editing, enhancing cancer treatment outcomes. - **Advancements in Regenerative Medicine**: CRISPR technologies are being explored for tissue repair and treatment of genetic diseases. - **Emerging CRISPR Therapies**: Ongoing clinical trials and research into CRISPR applications for genetic disorders, with nearly 60 studies listed on clinicaltrials.gov. - **PUMA Method**: A novel method for RNA detection using Cas12, expanding CRISPR applications in diagnostics. - **Integration of AI in CRISPR**: Using machine learning and genomic models to enhance CRISPR applications and predict gRNA effectiveness. - **CRISPRmap**: An innovative optical pooled screening method developed by the Gaublomme lab to investigate gene function within tissues. - **CRISPR-based diagnostics**: Innovative tests developed for rapid detection of diseases like Pneumocystis jirovecii pneumonia, improving diagnostic accuracy. ### Challenges and Concerns - **Off-Target Effects**: Ongoing research is focused on improving the precision of CRISPR systems to minimize unintended genetic changes. - **Potential for New Genetic Defects**: Research indicates that while CRISPR can repair genetic defects, it may inadvertently introduce new defects, highlighting the need for caution in clinical applications. - **Ethical Considerations**: CRISPR technology raises ethical concerns regarding genetic modifications and potential unintended consequences. - **Safety and Off-Target Effects**: Despite advancements, CRISPR technology faces challenges in ensuring safety and avoiding unintended genetic modifications that could lead to harmful effects. - **Regulatory Challenges**: Ongoing research is needed to enhance the precision and safety of CRISPR applications. - **Ethical and Regulatory Challenges**: CRISPR technology faces ethical concerns and regulatory hurdles that may impact its adoption and application. - **Public Acceptance**: The success of CRISPR technology relies on consumer acceptance and addressing criticisms regarding its blunt editing capabilities. - **Ethical Concerns**: The rapid advancement of CRISPR technology raises ethical questions regarding genetic modifications and unregulated DIY practices. - **Safety Issues**: CRISPR can inadvertently introduce new genetic defects, as seen in chronic granulomatous disease cases. - **Bias in CRISPR Guides**: Research indicates that CRISPR guides may not perform uniformly across different ancestries, potentially leading to oversights in cancer research. - **Regulatory Hurdles**: Complex regulatory requirements and limited healthcare access in developing countries pose challenges for CRISPR technology adoption. - **High R&D costs**: Significant financial investment required for developing and commercializing CRISPR technologies. - **Market Competition**: CRISPR companies face competition from emerging technologies and international players, particularly in biotech. - **Patent Restrictions**: In regions like India, researchers face challenges in utilizing CRISPR technologies due to patent restrictions and licensing rules. ## Related Topics [[CRISPR Technology]]